Other early-stage collaborations

We have a collaboration agreement with e-therapeutics, as announced in June 2020, to identify new therapeutic approaches to modulate a specific mechanism involved in IPF and potentially in other fibrotic indications. e-therapeutics will be responsible for all computational activities for the selected compounds. We will perform all experimental testing and are responsible for development and commercialization. Under the terms of the agreement, e-therapeutics received an upfront payment and is eligible to receive near-term payments plus pre-clinical, clinical, regulatory, and commercial milestone payments.